Gene Biotherapeutics, Inc.

CRXMOTCHealthcare

$0.00

+$0.00(+9900.00%)

Market Cap$6493

P/E Ratio—

52W High—

52W Low—

Avg Volume7

Open$0.00

Beta19.29

Earnings Financials Revenue

Gene Biotherapeutics, Inc. (CRXM) Earnings: Dates, EPS & Revenue History

Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.

CRXM · earnings · updated Jun 9, 2026

Latest Earnings

Q4 FY2020Report Date: Dec 31, 2020

EPS Actual

-$0.02

Revenue

—

Fiscal Period

Q4 FY2020

FY ends December

Report Date

Dec 31, 2020

After Market Close

CRXM reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.

Next Earnings Date

Days Away

days

Expected Date

Sep 1, 2026

Fiscal Period

Q3 FY2026

Release Time

◌ Time TBD (Unconfirmed)

EPS Est.

$-0.11

Rev. $0.17B

Days Away84

Expected DateSep 1, 2026

Fiscal PeriodQ3 FY2026

Release TimeTime TBD (Unconfirmed)

EPS Est.$-0.11

Rev. Est.$0.17B

EPS & Revenue vs. Estimates

Actual (Beat)

Actual (Miss)

Estimated

Earnings History

Period	Report Date	EPS Est.	EPS Actual	EPS Surpr.	Revenue	Rev. Est.	Rev. Surpr.
◌ Q2 FY2021	Apr 23, 2021	—	—	—	—	—	—
— Q4 FY2020	Dec 31, 2020	—	-$0.02	—	—	—	—
— Q3 FY2020	Sep 30, 2020	—	-$0.02	—	—	—	—
— Q2 FY2020	Jun 30, 2020	—	$0.00	—	—	—	—
— Q1 FY2020	Mar 31, 2020	—	-$0.01	—	—	—	—
— Q4 FY2019	Dec 31, 2019	—	$0.10	—	—	—	—
— Q3 FY2019	Sep 30, 2019	—	-$0.01	—	—	—	—
— Q2 FY2019	Jun 30, 2019	—	-$0.02	—	—	—	—

Q2 FY2021

Apr 23, 2021

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q4 FY2020

Dec 31, 2020

EPS Actual

-$0.02

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q3 FY2020

Sep 30, 2020

EPS Actual

-$0.02

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q2 FY2020

Jun 30, 2020

EPS Actual

$0.00

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q1 FY2020

Mar 31, 2020

EPS Actual

-$0.01

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q4 FY2019

Dec 31, 2019

EPS Actual

$0.10

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q3 FY2019

Sep 30, 2019

EPS Actual

-$0.01

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q2 FY2019

Jun 30, 2019

EPS Actual

-$0.02

EPS Est.

—

EPS Surpr.

—

Revenue

—

No analyst estimates available for CRXM.

Earnings Price Reaction

Closing price one trading day before vs. one trading day after each earnings release.

Period	Report Date	EPS Beat/Miss	Price Before	Price After	1D Reaction
— Q4 FY2020	Dec 31, 2020	—	$0.04	$0.04	+0.00%
— Q3 FY2020	Sep 30, 2020	—	$0.07	$0.06	-14.50%
— Q2 FY2020	Jun 30, 2020	—	$0.04	$0.04	-6.25%
— Q1 FY2020	Mar 31, 2020	—	$0.15	$0.15	-0.13%
— Q4 FY2019	Dec 31, 2019	—	$0.17	$0.19	+8.82%
— Q3 FY2019	Sep 30, 2019	—	$0.16	$0.16	+0.13%
— Q2 FY2019	Jun 30, 2019	—	$0.12	$0.13	+0.08%
— Q1 FY2019	Mar 31, 2019	—	$0.12	$0.12	-2.18%

Q4 FY2020+0.00%

Report Date

Dec 31, 2020

EPS Beat/Miss

—

Price Before

$0.04

Price After

$0.04

Q3 FY2020-14.50%

Report Date

Sep 30, 2020

EPS Beat/Miss

—

Price Before

$0.07

Price After

$0.06

Q2 FY2020-6.25%

Report Date

Jun 30, 2020

EPS Beat/Miss

—

Price Before

$0.04

Price After

$0.04

Q1 FY2020-0.13%

Report Date

Mar 31, 2020

EPS Beat/Miss

—

Price Before

$0.15

Price After

$0.15

Q4 FY2019+8.82%

Report Date

Dec 31, 2019

EPS Beat/Miss

—

Price Before

$0.17

Price After

$0.19

Q3 FY2019+0.13%

Report Date

Sep 30, 2019

EPS Beat/Miss

—

Price Before

$0.16

Price After

$0.16

Q2 FY2019+0.08%

Report Date

Jun 30, 2019

EPS Beat/Miss

—

Price Before

$0.12

Price After

$0.13

Q1 FY2019-2.18%

Report Date

Mar 31, 2019

EPS Beat/Miss

—

Price Before

$0.12

Price After

$0.12

Beat Rate0 / 8 quarters

Largest Move-14.50% (Q3 FY2020)

Data: FMP /historical-price-eod/full · field: close

About Earnings & Data Methodology

Gene Biotherapeutics, Inc. (CRXM) most recently reported earnings on December 31, 2020 for Q4 FY2020, posting EPS of $-0.02 (in line with the analyst consensus of —). The next CRXM earnings date is expected around September 1, 2026.

Each quarter, investors track CRXM earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CRXM revenue tab →

Earnings Glossary

EPS (Earnings Per Share)

Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.

Earnings Surprise %

(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.

Beat / Miss / In-Line

Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.

BMO / AMC

Before Market Open / After Market Close. Two windows when companies typically release results.

Fiscal Quarter

CRXM's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.

Analyst Consensus

Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.

Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.

Revenue Price history Financial statements Forecast Dividends Market cap

Frequently asked questions

CRXM earnings · 4 questions

Gene Biotherapeutics, Inc.'s next earnings report is expected around September 1, 2026. CRXM typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CRXM historically reports after market close (AMC).

CRXM earnings datewhen is CRXM earningsCRXM next earnings datewhen does CRXM report earningsCRXM earnings calendar

▸ Source: FMP · Gene Biotherapeutics, Inc. SEC filings · US GAAP · Gene Biotherapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026